Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chris Hyungseop Han picked up the Award of Excellence at the 74th Annual International Magnesium Association (IMA) World Magnesium Conference held in Singapore last month.

Dr. Jan Guy (Immediate Past President, Executive Committee Member, Board of Directors of IMA) (left) Chris Hyungseop Han (right)

The IMA Awards of Excellence program, established in 1962, is an annual program open to all researchers and companies demonstrating outstanding examples of magnesium's use. Nominations are judged by a peer review panel of international experts and winners are recognised worldwide. 

Chris won the award of excellence for his research in the development of Biodegradable Magnesium Alloy for Orthopaedic Applications. 

Often a patient will need two parts of their bones screwed together, which then results in a second operation to have the screws removed. For the past 8 years, Chris has been a part of a research team that overcame these limitations and created a roadmap to the next generation of metallic biodegradable implant materials with completely biocompatible elements. A state of the art method to synchronise the corrosion potential was developed to control the corrosion rate. 

Working closely with major hospitals in Korea, the research team have performed several hundred cases of small bone fixation screws and the results have been promising. The BBC World News ‘Horizons’ programme recently featured the team’s research as a medical breakthrough.

Chris commented:

"I am deeply honoured to have received the award of excellence from IMA. I would like to thank my family, my supervisors (Dr James Edwards and Professor Sion Glyn-Jones), my mentors at Korea Institute of Science and Technology (Dr. Hyun-Kwang Seok and Dr. Yu-Chan Kim) and the U&I Corporation for their support over the years. I am hoping to collaborate with more professionals at Oxford to explore the new possibilities of these biodegradable metallic materials." 

 

clinical Trial Published Clinical Trial Published on PNAS

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.